POLY-HF Trial Tests Triple-Drug Polypill for Heart Failure
A randomized controlled trial at two Texas hospitals has completed its evaluation of a single-capsule polypill designed to streamline treatment for patients with heart failure. The POLY-HF study (NCT04633005) enrolled 212 participants between November 2021 and October 2025, specifically targeting improvements in left ventricular ejection fraction (LVEF) through optimized guideline-directed medical therapy (GDMT).
Consolidating Empagliflozin, Spironolactone, and Metoprolol
The trial investigated whether a combination of empagliflozin, spironolactone, and metoprolol succinate could outperform enhanced usual care. Researchers formulated the polypill by encapsulating these three medications—10 mg of empagliflozin, 12.5 mg of spironolactone, and 25–150 mg of metoprolol succinate—into a single gel capsule. This method avoided chemical compounding, maintaining the integrity of individual drugs while allowing for flexible dosing. Participants were randomized 1:1, with the treatment group replacing their existing beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors with the new capsule.
Rigorous Assessment of Cardiac Function
To qualify, patients had to be at least 18 years old, symptomatic, and possess an LVEF ≤40%. Those with severe renal impairment or specific contraindications to GDMT were excluded. The primary outcome focused on LVEF at six months, verified through cardiac magnetic resonance (CMR). Secondary measures were extensive: researchers tracked HF hospitalizations, emergency department visits, all-cause mortality, quality of life via the KCCQ-OSS, and NT-proBNP levels. Functional capacity was assessed using the 6-minute walk test, with a win-ratio composite endpoint used to weigh mortality against LVEF gains.
Monitoring Adherence in Safety-Net Settings
The study design relied on in-person visits at 1, 3, and 6 months, during which physicians titrated GDMT to tolerable levels. To ensure data integrity, the team utilized therapeutic drug monitoring to verify medication adherence. Statistical analysis employed linear mixed-effects models and win-ratio methods. The researchers accounted for a 15% follow-up loss rate in their initial sample size calculations, ensuring the study remained robust despite the challenges of treating patients in safety-net hospital environments.
Simplifying Regimens to Combat Non-Adherence
Heart failure remains a primary driver of hospitalizations, yet patient adherence to complex GDMT regimens is frequently suboptimal. By packaging three distinct drug classes into one delivery vehicle, the POLY-HF trial seeks to lower the barrier to compliance. The data collected from this diverse patient population provides a template for future evaluations of multi-drug formulations. While full results await formal publication, the trial’s methodology offers a practical framework for potentially updating clinical guidelines and narrowing the gap in care for patients struggling with reduced LVEF.